5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges - PubMed (original) (raw)
Review
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges
Q Peng et al. Cancer. 1997.
Abstract
Background: Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years. PDT involves administration of a tumor-localizing photosensitizer or photosensitizer prodrug (5-aminolevulinic acid [ALA], a precursor in the heme biosynthetic pathway) and the subsequent activation of the photosensitizer by light. Although several photosensitizers other than ALA-derived protoprophyrin IX (PpIX) have been used in clinical PDT, ALA-based PDT has been the most active area of clinical PDT research during the past 5 years. Studies have shown that a higher accumulation of ALA-derived PpIX in rapidly proliferating cells may provide a biologic rationale for clinical use of ALA-based PDT and diagnosis. However, no review updating the clinical data has appeared so far.
Methods: A review of recently published data on clinical ALA-based PDT and diagnosis was conducted.
Results: Several individual studies in which patients with primary nonmelanoma cutaneous tumors received topical ALA-based PDT have reported promising results, including outstanding cosmetic results. However, the modality with present protocols does not in general, appear to be superior to conventional therapies with respect to initial complete response rates and long term recurrence rates, particularly in the treatment of nodular skin tumors. Topical ALA-PDT does have the following advantages over conventional treatments: it is noninvasive; it produces excellent cosmetic results; it is well tolerated by patients; it can be used to treat multiple superficial lesions in short treatment sessions; it can be applied to patients who refuse surgery or have pacemakers and bleeding tendency; it can be used to treat lesions in specific locations, such as the oral mucosa or the genital area; it can be used as a palliative treatment; and it can be applied repeatedly without cumulative toxicity. Topical ALA-PDT also has potential as a treatment for nonneoplastic skin diseases. Systemic administration of ALA does not seem to be severely toxic, but the advantage of using this approach for PDT of superficial lesions of internal hollow organs is still uncertain. The ALA-derived porphyrin fluorescence technique would be useful in the diagnosis of superficial lesions of internal hollow organs.
Conclusions: Promising results of ALA-based clinical PDT and diagnosis have been obtained. The modality has advantages over conventional treatments. However, some improvements need to be made, such as optimization of parameters of ALA-based PDT and diagnosis; increased tumor selectivity of ALA-derived PpIX; better understanding of light distribution in tissue: improvement of light dosimetry procedure; and development of simpler, cheaper, and more efficient light delivery systems.
Similar articles
- Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status.
Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG. Marcus SL, et al. J Clin Laser Med Surg. 1996 Apr;14(2):59-66. doi: 10.1089/clm.1996.14.59. J Clin Laser Med Surg. 1996. PMID: 9484077 Review. - The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Choudry K, Brooke RC, Farrar W, Rhodes LE. Choudry K, et al. Br J Dermatol. 2003 Jul;149(1):124-30. doi: 10.1046/j.1365-2133.2003.05351.x. Br J Dermatol. 2003. PMID: 12890205 Clinical Trial. - Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement.
Yang X, Palasuberniam P, Kraus D, Chen B. Yang X, et al. Int J Mol Sci. 2015 Oct 28;16(10):25865-80. doi: 10.3390/ijms161025865. Int J Mol Sci. 2015. PMID: 26516850 Free PMC article. Review. - Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.
Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, Deutsch TF, Anderson RR. Martin A, et al. Arch Dermatol Res. 1995;287(7):665-74. doi: 10.1007/BF00371740. Arch Dermatol Res. 1995. PMID: 8534131 Clinical Trial. - Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.
de Souza AL, Marra K, Gunn J, Samkoe KS, Kanick SC, Davis SC, Chapman MS, Maytin EV, Hasan T, Pogue BW. de Souza AL, et al. Br J Cancer. 2016 Sep 27;115(7):805-13. doi: 10.1038/bjc.2016.267. Epub 2016 Aug 30. Br J Cancer. 2016. PMID: 27575852 Free PMC article.
Cited by
- Description of mitochondrial oxygen tension and its variability in healthy volunteers.
Baysan M, Broere M, Wille ME, Bergsma JE, Mik EG, Juffermans NP, Tsonaka R, van der Bom JG, Arbous SM. Baysan M, et al. PLoS One. 2024 Jun 3;19(6):e0300602. doi: 10.1371/journal.pone.0300602. eCollection 2024. PLoS One. 2024. PMID: 38829894 Free PMC article. Clinical Trial. - A handheld device for intra-cavity and ex vivo fluorescence imaging of breast conserving surgery margins with 5-aminolevulinic acid.
Gibson C, Wang SC, Phoon A, Thalanki Anantha N, Ottolino-Perry K, Petropoulos S, Qureshi Z, Subramanian V, Shahid A, O'Brien C, Carcone S, Chung S, Tsui T, Son V, Sukhram M, Meng F, Done SJ, Easson AM, Cil T, Reedijk M, Leong WL, DaCosta RS. Gibson C, et al. BMC Biomed Eng. 2024 Jun 1;6(1):5. doi: 10.1186/s42490-024-00079-9. BMC Biomed Eng. 2024. PMID: 38822389 Free PMC article. - Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy.
Mørk E, Mjønes P, Foss OA, Mørk C, Bachmann IM, Kroon S, Dotterud LK, Helsing P, Vatne Ø, Christensen E. Mørk E, et al. Acta Derm Venereol. 2024 May 15;104:adv18308. doi: 10.2340/actadv.v104.18308. Acta Derm Venereol. 2024. PMID: 38751175 Free PMC article. - Challenges and opportunities of bioprocessing 5-aminolevulinic acid using genetic and metabolic engineering: a critical review.
Yi YC, Shih IT, Yu TH, Lee YJ, Ng IS. Yi YC, et al. Bioresour Bioprocess. 2021 Oct 13;8(1):100. doi: 10.1186/s40643-021-00455-6. Bioresour Bioprocess. 2021. PMID: 38650260 Free PMC article. Review. - Highways and Detours in the Realm of Photodynamic Therapy.
Kessel D, Peng Q. Kessel D, et al. Int J Mol Sci. 2024 Mar 8;25(6):3119. doi: 10.3390/ijms25063119. Int J Mol Sci. 2024. PMID: 38542092 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous